Peijia Medical Limited

DB:4WO Stock Report

Market Cap: €297.3m

Peijia Medical Valuation

Is 4WO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4WO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4WO (€0.47) is trading below our estimate of fair value (€2.02)

Significantly Below Fair Value: 4WO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4WO?

Key metric: As 4WO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4WO. This is calculated by dividing 4WO's market cap by their current revenue.
What is 4WO's PS Ratio?
PS Ratio4.4x
SalesCN¥517.46m
Market CapCN¥2.28b

Price to Sales Ratio vs Peers

How does 4WO's PS Ratio compare to its peers?

The above table shows the PS ratio for 4WO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
SBS Stratec
1.5x7.7%€382.3m
EUZ Eckert & Ziegler
3.3x6.3%€918.9m
PUS PULSION Medical Systems
3.7xn/a€134.4m
DRW3 Drägerwerk KGaA
0.2x4.2%€789.2m
4WO Peijia Medical
4.4x29.0%€2.4b

Price-To-Sales vs Peers: 4WO is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 4WO's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$834.58m
PHH2 Paul Hartmann
0.3xn/aUS$788.03m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
4WO 4.4xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4WO is expensive based on its Price-To-Sales Ratio (4.4x) compared to the European Medical Equipment industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 4WO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4WO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4WO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4WO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.47
€0.57
+21.0%
30.2%€0.87€0.47n/a4
Nov ’25€0.43
€0.57
+33.4%
30.2%€0.87€0.47n/a4
Oct ’25€0.40
€0.57
+42.7%
30.2%€0.87€0.47n/a4
Sep ’25n/a
€0.65
0%
48.5%€1.20€0.46n/a4
Aug ’25n/a
€0.75
0%
43.9%€1.21€0.50n/a3
Jul ’25n/a
€1.27
0%
12.1%€1.48€1.12n/a3
Jun ’25n/a
€1.44
0%
16.9%€1.70€1.11n/a3
May ’25n/a
€1.44
0%
16.9%€1.70€1.11n/a3
Apr ’25n/a
€1.51
0%
15.7%€1.81€1.12n/a5
Mar ’25n/a
€1.51
0%
15.7%€1.81€1.12n/a5
Feb ’25n/a
€1.56
0%
9.6%€1.79€1.40n/a5
Jan ’25n/a
€1.55
0%
9.6%€1.78€1.39n/a5
Dec ’24n/a
€1.55
0%
9.2%€1.77€1.41n/a5
Nov ’24€0.86
€1.55
+79.4%
9.2%€1.77€1.41€0.435
Oct ’24€0.83
€1.55
+85.9%
9.2%€1.77€1.41€0.405
Sep ’24€0.81
€1.58
+93.4%
7.0%€1.76€1.42n/a5
Aug ’24€1.07
€1.56
+45.5%
7.0%€1.73€1.39n/a5
Jul ’24€0.72
€1.62
+125.0%
5.4%€1.76€1.50n/a5
Jun ’24€0.79
€1.65
+109.2%
4.1%€1.74€1.55n/a5
May ’24€1.09
€1.66
+52.3%
5.1%€1.75€1.52n/a5
Apr ’24€1.09
€1.71
+57.1%
3.4%€1.79€1.62n/a5
Mar ’24€1.32
€1.48
+12.4%
26.5%€1.80€0.83n/a4
Feb ’24€1.40
€1.43
+1.9%
25.2%€1.75€0.82n/a4
Jan ’24€1.10
€1.32
+20.1%
24.0%€1.71€0.87n/a4
Dec ’23€0.94
€1.32
+40.6%
24.0%€1.71€0.87n/a4
Nov ’23€0.83
€1.32
+59.2%
24.0%€1.71€0.87€0.864

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

1.0%

1Y

-34.2%

LNA Santé

€234.2m

Engages in the management and operation of health establishments.

2N3

€22.30

7D

-4.9%

1Y

16.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%